Research Study Summary
WVU11310-Once daily intravenous Busulfex as part of reduced toxicity conditioning for patients with relapsed/refractory Hodgkin and non-Hodgkin lymphomas undergoing allogeneic hematopoietic cell transplantation - A multicenter phase II study.
Primary Objective: To assess 1-year progression free survival of patients with chemotherapy refractory Hodgkin and non-Hodgkin lymphomas undergoing reduced-toxicity conditioning with once daily Busulfex and fludarabine
To Learn more
CW ID: 169037
Date Last Changed:
July 23, 2013
Clinical Trial Snapshot
- Both Male and Female
- Overall Status
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.